Entegris Inc vs Humana Inc — how do they compare? Entegris Inc trades at $165.15 (market cap $24.78B), while Humana Inc trades at $434.75 (market cap $46.49B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Humana Inc for 51 Days on average.
| ENTG | HUM | |
|---|---|---|
Market Cap | $24.78B | $46.49B |
Volume | 2,648,320 | 2,567,704 |
Sector | Technology | Health |
52-Week High | $184.00 | $409.85 |
52-Week Low | $68.80 | $163.67 |
Typical Hold Time | 41 Days | 51 Days |
Enterprise Value | $27.99B | $53.84B |
Dividend Yield | 0.25% | 0.91% |
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $164.22, down 1.26% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected soon. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Analysts maintain a strong buy consensus with a $182.43 price target, indicating potential upside.
The outlook for ENTG is positive, driven by AI-related semiconductor demand and operational improvements. Key risks include high valuation multiples and exposure to semiconductor cycle volatility. Institutional accumulation and recent patent defenses support confidence, but investors should monitor execution against earnings expectations and industry capital spending trends.
Humana (HUM) trades at $436.00, up 9.96% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has grown to $129.66 billion in 2025, though net income margin compressed to 0.88%. Analyst consensus is a buy with a $457.05 price target, and recent news highlights a Barclays upgrade and dividend declaration.
The outlook is positive given earnings momentum and institutional interest, but risks include margin pressure and regulatory scrutiny. Upside potential exists if the company maintains enrollment growth and cost controls, though investors should monitor Medicare Advantage plan changes and competitive dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →